Integra LifeSciences (NASDAQ:IART) Releases FY 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.410-2.510 for the period, compared to the consensus estimate of 2.510. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its FY25 guidance to $2.41 to $2.51 EPS.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Morgan Stanley started coverage on Integra LifeSciences in a research note on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective on the stock. Citigroup upped their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Price Performance

IART stock traded up $2.31 during trading on Tuesday, reaching $24.36. 202,650 shares of the company were exchanged, compared to its average volume of 551,138. The stock’s 50 day moving average price is $23.68 and its 200 day moving average price is $21.81. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The company has a market cap of $1.88 billion, a P/E ratio of -269.58, a PEG ratio of 0.73 and a beta of 1.17. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $44.91.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.11. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. During the same period in the prior year, the firm earned $0.89 EPS. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. As a group, analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. This represents a 2.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 3.10% of the stock is currently owned by company insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.